サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790314

臨床腫瘍次世代シーケンシングの市場規模、シェア、動向分析レポート：ワークフロー別、技術別、用途別、最終用途別、地域別、セグメント別予測、2025年～2033年

Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis), By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 125 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
臨床腫瘍次世代シーケンシングの市場規模、シェア、動向分析レポート：ワークフロー別、技術別、用途別、最終用途別、地域別、セグメント別予測、2025年～2033年
出版日: 2025年07月03日
発行: Grand View Research
ページ情報: 英文 125 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

臨床腫瘍次世代シーケンシング市場のサマリー

世界の臨床腫瘍次世代シーケンシング市場規模は、2024年に4億8,230万米ドルと推計され、2033年には19億3,020万米ドルに達し、2025年から2033年にかけて16.77%のCAGRで成長すると予測されています。臨床腫瘍次世代シーケンシング（NGS）産業の成長をもたらす主な要因は、技術進歩の増加、企業間の競合の激化、ヘルスケア支出の増加、がん有病率の上昇です。

また、ソリューションを発明するための研究開発活動の強化は、予測期間中の市場成長を促進すると予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

  • 市場の系譜
    • 親市場分析
    • 補助市場分析
  • 臨床腫瘍次世代シーケンシング市場-市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 市場分析ツール
    • ポーターのファイブフォース分析
    • PESTLE分析
    • COVID-19の影響分析

第4章 臨床腫瘍次世代シーケンシング市場：ワークフロービジネス分析

  • ワークフローセグメントダッシュボード
  • 世界の臨床腫瘍次世代シーケンシング市場のワークフロー変動分析、2024年および2033年
  • 世界の臨床腫瘍次世代シーケンシング市場規模と動向分析（ワークフロー別、2021～2033年）
  • NGSプレシーケンシング
  • NGSシーケンシング
  • NGSデータ分析

第5章 臨床腫瘍次世代シーケンシング市場：技術ビジネス分析

  • テクノロジーセグメントダッシュボード
  • 世界の臨床腫瘍次世代シーケンシング市場の技術変動分析、2024年および2033年
  • 世界の臨床腫瘍次世代シーケンシング市場規模と動向分析（技術別、2021～2033年）
  • 全ゲノム配列解析
  • 全エクソームシーケンシング
  • ターゲットシーケンシングとリシーケンシング

第6章 臨床腫瘍次世代シーケンシング市場：用途ビジネス分析

  • 用途セグメントダッシュボード
  • 世界の臨床腫瘍次世代シーケンシング市場用途変動分析、2024年および2033年
  • 世界の臨床腫瘍次世代シーケンシング市場規模と動向分析（用途別、2021～2033年）
  • スクリーニング
  • コンパニオン診断
  • その他

第7章 臨床腫瘍次世代シーケンシング市場：最終用途ビジネス分析

  • 最終用途セグメントダッシュボード
  • 世界の臨床腫瘍次世代シーケンシング市場の最終用途変動分析、2024年および2033年
  • 世界の臨床腫瘍次世代シーケンシング市場規模と動向分析（最終用途別、2021～2033年）
  • クリニック
  • 病院
  • 研究所

第8章 臨床腫瘍次世代シーケンシング市場：地域別

  • 地域別市場シェア分析、2024年および2033年
  • 地域市場ダッシュボード
  • 市場規模、予測、動向分析、2021～2033年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 競合情勢

  • 企業/競合の分類
  • 戦略マッピング
  • 企業市況分析、2024年
  • 企業プロファイル/上場企業
    • Thermo Fisher Scientific Inc.
    • Illumina, Inc.
    • Myriad Genetics
    • F. Hoffmann-La Roche Ltd.
    • Agilent Technologies, Inc.
    • Perkin Elmer
    • Pacific Bioscience
    • Oxford Nanopore Technologies Ltd.
    • Eurofins Scientific SE
    • Qiagen NV
図表

List of Tables

  • TABLE 1 Global clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 2 Global clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 3 Global clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 4 Global clinical oncology NGS screening market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 5 Global clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 6 North America clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 7 North America clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 8 North America clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 9 North America clinical oncology NGS screening market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 10 North America clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 11 The U.S. clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 12 The U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 13 The U.S. clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 14 The U.S. clinical oncology NGS screening market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 15 The U.S. clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 16 Canada clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 17 Canada clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 18 Canada clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 19 Canada clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 20 Mexico clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 21 Mexico clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 22 Mexico clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 23 Mexico clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 24 Europe clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 25 Europe clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 26 Europe clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 27 Europe clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 28 Germany clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 29 Germany clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 30 Germany clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 31 Germany clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 32 UK clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 33 UK clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 34 UK clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 35 UK clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 36 France clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 37 France clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 38 France clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 39 France clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 40 Italy clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 41 Italy clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 42 Italy clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 43 Italy clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 44 Spain clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 45 Spain clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 46 Spain clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 47 Spain clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 48 Denmark clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 49 Denmark clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 50 Denmark clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 51 Denmark clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 52 Sweden clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 53 Sweden clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 54 Sweden clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 55 Sweden clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 56 Norway clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 57 Norway clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 58 Norway clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 59 Norway clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 60 Asia Pacific clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 61 Asia Pacific clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 62 Asia Pacific clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 63 Asia Pacific clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 64 Japan clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 65 Japan clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 66 Japan clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 67 Japan clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 68 China clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 69 China clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 70 China clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 71 China clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 72 India clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 73 India clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 74 India clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 75 India clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 76 South Korea clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 77 South Korea clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 78 South Korea clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 79 South Korea clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 80 Australia clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 81 Australia clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 82 Australia clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 83 Australia clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 84 Thailand clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 85 Thailand clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 86 Thailand clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 87 Thailand clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 88 Latin America clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 89 Latin America clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 90 Latin America clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 91 Latin America clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 92 Brazil clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 93 Brazil clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 94 Brazil clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 95 Brazil clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 96 Argentina clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 97 Argentina clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 98 Argentina clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 99 Argentina clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 100 Middle East & Africa clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 101 Middle East & Africa clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 102 Middle East & Africa clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 103 Middle East & Africa clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 104 South Africa clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 105 South Africa clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 106 South Africa clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 107 South Africa clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 108 Saudi Arabia clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 109 Saudi Arabia clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 110 Saudi Arabia clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 111 Saudi Arabia clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 112 UAE clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 113 UAE clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 114 UAE clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 115 UAE clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
  • TABLE 116 Kuwait clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • TABLE 117 Kuwait clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
  • TABLE 118 Kuwait clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
  • TABLE 119 Kuwait clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)

List of Figures

  • FIG. 1 Market snapshot
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Market trends & outlook
  • FIG. 7 Market segmentation & scope
  • FIG. 8 Market restraint relevance analysis (Current & future impact)
  • FIG. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • FIG. 10 Porter's five forces analysis
  • FIG. 11 Strategy framework
  • FIG. 12 Participant categorization
  • FIG. 13 Clinical oncology NGS market: Technology outlook key takeaways
  • FIG. 14 Clinical oncology NGS market: Technology movement analysis
  • FIG. 15 Whole genome sequencing for clinical oncology market, 2021 - 2033 (USD Million)
  • FIG. 16 Whole exome sequencing for clinical oncology market, 2021 - 2033 (USD Million)
  • FIG. 17 Targeted sequencing and resequencing for clinical oncology market, 2021 - 2033 (USD Million)
  • FIG. 18 Clinical oncology NGS market: Workflow outlook key takeaways
  • FIG. 19 Clinical oncology NGS market: Workflow movement analysis
  • FIG. 20 NGS pre-sequencing for clinical oncology market, 2021 - 2033 (USD Million)
  • FIG. 21 NGS sequencing for clinical oncology market, 2021 - 2033 (USD Million)
  • FIG. 22 NGS data analysis for clinical oncology market, 2021 - 2033 (USD Million)
  • FIG. 23 Clinical oncology NGS market: Application outlook key takeaways
  • FIG. 24 Clinical oncology NGS market: Application movement analysis
  • FIG. 25 Screening clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 26 Sporadic cancer screening clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 27 Inherited cancer screening clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 28 Companion diagnostics clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 29 Other diagnostics clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 30 Clinical oncology NGS market: End use outlook key takeaways
  • FIG. 31 Clinical oncology NGS market: End use movement analysis
  • FIG. 32 Hospitals clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 33 Clinics clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 34 Laboratories clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 35 Regional marketplace: Key takeaway
  • FIG. 36 Clinical oncology NGS market: Regional outlook, 2024 & 2033
  • FIG. 37 North America clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 38 U.S. clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 39 Canada clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 40 Mexico clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 41 Europe clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 42 Germany clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 43 UK clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 44 France clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 45 Italy clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 46 Spain clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 47 Denmark clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 48 Sweden clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 49 Norway clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 50 Asia Pacific clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 51 Japan clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 52 China clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 53 India clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 54 South Korea clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 55 Australia clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 56 Thailand clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 57 Latin America clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 58 Brazil clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 59 Argentina clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 60 Middle East & Africa clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 61 South Africa clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 62 Saudi Arabia clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 63 UAE clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 64 Kuwait clinical oncology NGS market, 2021 - 2033 (USD Million)
  • FIG. 65 Key companies profiled
目次
Product Code: GVR-3-68038-791-9

Clinical Oncology Next Generation Sequencing Market Summary

The global clinical oncology next generation sequencing market size was estimated at USD 482.3 million in 2024 and is projected to reach USD 1,930.2 million by 2033, growing at a CAGR of 16.77% from 2025 to 2033. The key drivers responsible for the growth of the clinical oncology next generation sequencing (NGS) industry are increasing technological advancements, growing competition among players, increasing healthcare spending, and the rise in the prevalence of cancer.

In addition, augmenting research & development activities to invent solutions is expected to fuel the market growth over the forecast period.

Global Clinical Oncology Next Generation Sequencing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and analyzes the latest industry trends in each sub-segment from 2021 to 2033. Grand View Research has segmented the global clinical oncology next generation sequencing market report based on workflow, technology, application, end use, and region.

  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • NGS Pre-Sequencing
  • NGS Sequencing
  • NGS Data Analysis
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing & Resequencing
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Screening
    • Sporadic Cancer
    • Inherited Cancer
  • Companion Diagnostics
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Clinics
  • Laboratories
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Workflow Segment
    • 1.2.2. Technology Segment
    • 1.2.3. Application Segment
    • 1.2.4. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segmental Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, and Scope

  • 3.1. Market Lineage
    • 3.1.1. Parent Market Analysis
    • 3.1.2. Ancillary Market Analysis
  • 3.2. Clinical Oncology NGS Market- Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Clinical Oncology NGS Market: Workflow Business Analysis

  • 4.1. Workflow Segment Dashboard
  • 4.2. Global Clinical Oncology NGS Market Workflow Movement Analysis, 2024 & 2033
  • 4.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
  • 4.4. NGS Pre-Sequencing
    • 4.4.1. Global NGS Pre-Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.5. NGS Sequencing
    • 4.5.1. Global NGS Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. NGS Data Analysis
    • 4.6.1. Global NGS Data Analysis Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Clinical Oncology NGS Market: Technology Business Analysis

  • 5.1. Technology Segment Dashboard
  • 5.2. Global Clinical Oncology NGS Market Technology Movement Analysis, 2024 & 2033
  • 5.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 5.4. Whole Genome Sequencing
    • 5.4.1. Global Whole Genome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Whole Exome Sequencing
    • 5.5.1. Global Whole Exome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Targeted Sequencing & Resequencing
    • 5.6.1. Global Targeted Sequencing & Resequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Clinical Oncology NGS Market: Application Business Analysis

  • 6.1. Application Segment Dashboard
  • 6.2. Global Clinical Oncology NGS Market Application Movement Analysis, 2024 & 2033
  • 6.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 6.4. Screening
    • 6.4.1. Global Screening Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Companion Diagnostics
    • 6.5.1. Global Companion Diagnostics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. Sporadic Cancer
      • 6.5.2.1. Global Sporadic Cancer Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Inherited Cancer
      • 6.5.3.1. Global Inherited Cancer Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Global Others Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Clinical Oncology NGS Market: End Use Business Analysis

  • 7.1. End Use Segment Dashboard
  • 7.2. Global Clinical Oncology NGS Market End Use Movement Analysis, 2024 & 2033
  • 7.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 7.4. Clinics
    • 7.4.1. Global Clinics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Hospitals
    • 7.5.1. Global Hospitals Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Laboratories
    • 7.6.1. Global Laboratories Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Clinical Oncology NGS Market: Regional Estimates & Trend Analysis by Workflow, Technology, Application, and End Use

  • 8.1. Regional Market Share Analysis, 2024 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts, Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Competitive scenario
      • 8.4.2.3. Regulatory framework
      • 8.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Competitive scenario
      • 8.4.3.3. Regulatory framework
      • 8.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Competitive scenario
      • 8.4.4.3. Regulatory framework
      • 8.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Competitive scenario
      • 8.5.2.3. Regulatory framework
      • 8.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Competitive scenario
      • 8.5.3.3. Regulatory framework
      • 8.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Competitive scenario
      • 8.5.4.3. Regulatory framework
      • 8.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Competitive scenario
      • 8.5.5.3. Regulatory framework
      • 8.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Competitive scenario
      • 8.5.6.3. Regulatory framework
      • 8.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Competitive scenario
      • 8.5.7.3. Regulatory framework
      • 8.5.7.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Competitive scenario
      • 8.5.8.3. Regulatory framework
      • 8.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key country dynamics
      • 8.5.9.2. Competitive scenario
      • 8.5.9.3. Regulatory framework
      • 8.5.9.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Competitive scenario
      • 8.6.2.3. Regulatory framework
      • 8.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Competitive scenario
      • 8.6.3.3. Regulatory framework
      • 8.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Competitive scenario
      • 8.6.4.3. Regulatory framework
      • 8.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Competitive scenario
      • 8.6.5.3. Regulatory framework
      • 8.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Competitive scenario
      • 8.6.6.3. Regulatory framework
      • 8.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Competitive scenario
      • 8.6.7.3. Regulatory framework
      • 8.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Competitive scenario
      • 8.7.2.3. Regulatory framework
      • 8.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Competitive scenario
      • 8.7.3.3. Regulatory framework
      • 8.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Competitive scenario
      • 8.8.2.3. Regulatory framework
      • 8.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Competitive scenario
      • 8.8.3.3. Regulatory framework
      • 8.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Competitive scenario
      • 8.8.4.3. Regulatory framework
      • 8.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key country dynamics
      • 8.8.5.2. Competitive scenario
      • 8.8.5.3. Regulatory framework
      • 8.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2024
  • 9.4. Company Profiles/Listing
    • 9.4.1. Thermo Fisher Scientific Inc.
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Illumina, Inc.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Myriad Genetics
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. F. Hoffmann-La Roche Ltd.
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Agilent Technologies, Inc.
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Perkin Elmer
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Pacific Bioscience
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Oxford Nanopore Technologies Ltd.
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Eurofins Scientific S.E.
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Qiagen N.V.
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives